High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced null-responder HIV/HCV genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.
Fiche publication
Date publication
mai 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM
Lien Pubmed
Résumé
BACKGROUND: Few direct anti-HCV agents have been studied in difficult-to-treat, null responders and cirrhotic HIV co-infected patients. Daclatasvir and asunaprevir combined with pegylated interferon-ribavirin (PR) have shown promising results in HCV mono-infected patients. METHODS: An open-label, single-arm, phase-2 study was conducted in HIV/HCV genotype 1/4 co-infected patients, null responders to prior PR standard therapy, on a raltegravir-based regimen with HIV RNA
Référence
Clin Infect Dis. 2015 May 14. pii: civ381.